FOXX vs XTLB vs AEYE vs IDN vs ALKT

For growth investors, Foxx Development Holdings Inc.

(FOXX) is the stronger pick with 1941% revenue growth year-over-year, versus -100. 0% for Intellicheck, Inc. (IDN). Analysts rate Intellicheck, Inc. (IDN) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Intellicheck, Inc.

(IDN) delivered a total return of -4. 1%, compared to -80. 4% for XTL Biopharmaceuticals Ltd. (XTLB). Over 10 years, the gap is even starker: IDN returned +301. 1% versus XTLB's -87. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Intellicheck, Inc.

(IDN) is the lower-risk stock at 0. 33β versus AudioEye, Inc. 's 2. 18β — meaning AEYE is approximately 568% more volatile than IDN relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 98% for Alkami Technology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Foxx Development Holdings Inc.

(FOXX) is pulling ahead at 1941% versus -100. 0% for Intellicheck, Inc. (IDN). On earnings-per-share growth, the picture is similar: Intellicheck, Inc. grew EPS 100. 0% year-over-year, compared to -212. 8% for Foxx Development Holdings Inc.. Over a 3-year CAGR, FOXX leads at 72. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intellicheck, Inc.

(IDN) is the more profitable company, earning 0. 0% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDN leads at 0. 0% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Alkami Technology, Inc.

(ALKT) trades at 21. 7x forward P/E versus 75. 2x for Intellicheck, Inc. — 53. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALKT: 26. 2% to $22. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Intellicheck, Inc.

(IDN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 33), +301. 1% 10Y return). AudioEye, Inc. (AEYE) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IDN: +301. 1%, AEYE: +96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (FOXX (Technology) and XTLB (Healthcare) and AEYE (Technology) and IDN (Technology) and ALKT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: FOXX is a small-cap high-growth stock; XTLB is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; IDN is a small-cap quality compounder stock; ALKT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.